Payers do not reimburse based on red blood cell size
In total, 51% ( n = 163) of trial participants were enrolled in Europe and Australia, 36% ( n = 116) in North America and 13% ( n = 41) in Japan
According to NICE guidance (NG28), the continuation of GLP-1 receptor agonist therapy in type 2 diabetes should be assessed after six months, with treatment continued only if there is a reduction in HbA1c of at least 11 mmol/mol (1%) and, where applicable, a weight loss of at least 3% of initial body weight
Purity: 99.93% CAS No.: 618913-30-7 Formula: C 10 H 12 N 4 O 2 S Molecular Weight:252.29 Storage:Powder -20C, 3 years , 4C, 2 years
If you're looking at somebody with an eating disorder like anorexia, that's a different conversation
Improving cardiovascular health, which GLP-1s already support